Highlights Ventyx Biosciences, Inc.

Equities

VTYX

US92332V1070

Real-time Estimate Cboe BZX Other stock markets 12:26:37 2024-06-10 pm EDT			5-day change	1st Jan Change
3.28 ^USD	+0.61%		-34.44%	+31.38%

Jun. 06	Oppenheimer Adjusts Ventyx Biosciences Price Target to $10 From $12, Maintains Outperform Rating	MT
Jun. 05	Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results	Jun. 05	MT
Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers	Jun. 05	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event	Mar. 11	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Ventyx Biosciences, Inc. Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis	Nov. 06	CI
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative Colitis	23-10-09	CI
Ventyx Biosciences Q2 Net Loss Widens	23-08-10	MT
Ventyx Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Ventyx Biosciences, Inc. Announces Initiation of Dosing in A Phase 1 Trial of VTX3232, A Novel CNS-Penetrant NLRP3 Inhibitor	23-06-14	CI
Ventyx Biosciences Q1 Loss Widens	23-05-11	MT
Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Ventyx Biosciences, Inc. acquired Zomagen Biosciences Ltd.	23-04-13	CI
VENTYX BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-23	AQ
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors	23-01-12	AQ
Ventyx Biosciences, Inc Announces Dosing of the First Patient in the Phase 2 Serenity Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis	22-12-01	CI
VENTYX BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ventyx Biosciences, Inc.

Equities

VTYX

US92332V1070

Highlights

Filters